Immupharma Share Discussion Threads

[lucicavi] 24/1/2018 15:22

Yes the downside is less scary now, upside is HUGE

[poacher45] 24/1/2018 15:20

I understand why people are unhappy with the rights issue but it has strengthened Immupharma's bargaining hand. The thing that surprises me today is the number of shares traded. This could reach 4000000 by the end of the day and proves there is a lot of demand. I tend to think that several institutions wanted stakes in this company. It would have been impossible to buy that amount without paying a very high price on the market. I think it is a win win situation for Immupharma and the shareholders. Anybody else wanting a large shareholding will now have to pay the proper price probably £2 a share before the results.

[lucicavi] 24/1/2018 15:06

Dare I say it, we could go blue today

L2 firming and buys entering

[lucicavi] 24/1/2018 14:46

Nicely put che7win

[che7win] 24/1/2018 14:43

If they sell to only 50k patients at $20,000, that is $1bn revenue.50k out of 1,500,000 possible patients isn't a big ask, unrealistically low.Margins are extremely high, but lets say only 50% profit that is half a billion dollars profits per year.That alone gets us to £45 PER SHARE.Thay is why Tim says Upside is exponential.

[opodio] 24/1/2018 14:39

be amazing if news is next week the £10m buyer will be making £100m, nice work. Wonder if it was a pal?

[che7win] 24/1/2018 14:36

Really i wouldnt be surprised if these should go blue today

[opodio] 24/1/2018 14:35

Buying 10,000 IMMUPHARMA ORD GBP0.10 shares
A firm electronic quote is not currently available for your order
You can send this order without a price limit by clicking the 'Place Order' button below, or alternatively click 'Amend' to go back and specify a limit price

[john09] 24/1/2018 14:28

On the way up

[tjbird] 24/1/2018 14:28

Flying

Be nice to see it go blue today

[che7win] 24/1/2018 14:22

We are currently valued on a fully diluted basis at £200mI value lupuzor at £5b on a successful outcome.The rest of the P140 platform for diabetes, cancer etc at this junction must be worth £1b if Lupuzor proves P140 platform.So £6b is 30 times the current market cap, £42 possible per share. For that reason, I'm a buyer.No wonder Tim talks about exponential market cap increase and institutions are knocking on IMMs door willing to throw money at them.All uncertainty out of the way, the only reason the share stopped at 187p was because of the fund raise.Current price lets us in at same price as institutions.For this reason, I think we will rise sharply really of the week.

[w1ndjammer] 24/1/2018 14:18

To many whingers on this thread, you should have done your research into
Sylviane Muller and p140 then you could sit back and enjoy.

WJ.

[sportbilly1976] 24/1/2018 14:18

NY Boy24 Jan '18 - 13:22 - 10982 of 10998

FCA will no doubt be looking into possible insider trading if some traders have been found out to have benefitted financially short selling on leaked news. I guess they wouldn’t be so silly though."


You are joking right? How many FCA investigations do you think there have been on such activities for a small cap company which institutions and individuals really have been fined for?

I bet I've more fingers on one hand :)

[jimmmy] 24/1/2018 14:16

level 2 getting stronger, hopefully finish higher

[che7win] 24/1/2018 14:14

As announced on 26 September 2017, with the trial progressing on track, ImmuPharma is planning ahead in anticipation of the trial's successful outcome. In consultation with our regulatory advisors, we are now progressing the completion of the regulatory dossiers in preparation for submission to the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).  This includes the finalisation of the Drug Master File (DMF) and in particular the manufacture of commercial batches of the LupuzorTMdrug.  These will be manufactured according to described procedures in the DMF, to be ready for inclusion in the Company's regulatory submissions. ImmuPharma expects to have the first set of batches ready by the end of Q1 2018 in line with Lupuzor'sTM Phase III top line results being announced. 

[greedfear] 24/1/2018 14:11

The new institutions that approached IMM probably were sellers at higher SP's. Same old, same old.

[chalky230] 24/1/2018 14:11

From NY boy link
Interesting they actually used the wording "Top Line results)


NORTHLAND VIEW

ImmuPharma has completed a fundraise of £10 million (before expenses) through a placing of 6,944,445 new ordinary shares at a price of 144p per share with new and existing investors.
The funds will provide additional working capital and support investment into the potential use of the Company’s P140 peptide platform in disease areas outside lupus.
The Company recently announced the completion of a Phase III clinical trial testing the use of P140 (Lupuzor™), against Lupus, an autoimmune disease. The study remains on track to report top line results in Q1-2018.
With the Company recently completing a Phase III trial in lupus, a significant milestone, this placing strengthens ImmuPharma’s balance sheet and provides funds to investigate the extension of the P140 peptide platform in disease areas outside lupus. Should Lupuzor™ successfully meet the Phase III trial endpoints, this will put the Company in a strong negotiating position with potential partners.

COMPANY DESCRIPTION
ImmuPharma PLC is a late clinical stage drug development business specialising in the area of autoimmune disease.

[aviemore32] 24/1/2018 14:05

Well, my timing was impeccable. First post here yesterday about not having bought as many of these as I wanted at under 50p and immediately got the chance for a few more at less than I was expecting. I had ended up with a few too many JOG so trimmed them and added here with the funds. We PIs just have to suck it up when it comes to placements, they are a fact of life on AIM.

Virtually all of my portfolio is now stable and waiting for news over the next 3,6,9 months. This is one of my real potential biggies, but only time will tell.

GLA
avie

[ny boy] 24/1/2018 14:01

Positive on the institutional placing

[englishlongbow] 24/1/2018 13:51

Sylviane Muller said at the Lupuzor Symposium they could go straight into Phase 2b or 3 for the other P140 indications.

46 min 15 sec:

[glennrcharles] 24/1/2018 13:48

Any idea how much the phase 3 trial has cost them? Would they have money to start up a new trial for another indication? Is it true that they can miss out stage 1? As lupizor is safe. Could they move straight to phase 3 for another indication?

[top tips] 24/1/2018 13:47

IMM's P140 platform looks to be worth more than Kite's was.

[njb67] 24/1/2018 13:46

ELB
You are twisting my words. Gilead bought Kite for their platform, quite true. I also said that platforms will vary in value so you can not make any inference from the Kite deal on the value of IMM.

Funny how all the ramping gang turn up at the same time. What a coincidence that they post here within minutes of each other. Perfect synchronicity.

[top tips] 24/1/2018 13:41

It improves the prospects because they are broadening their P140 interest and provides another top up opportunity. Best thing as I see it, is to keep buying whatever the price. Institutions prepared to pay 144p in the current placing against 52p in last year's placing.